|
|
|
|
|
|
|
M T W Th Fri |
|
31 July, 2026 |
|
|
sponsored by
|
|
|
|
Meet a Different Brand of Experts
|
| At Cambrex, our commitment to pushing the boundaries of what’s possible sets us apart as a leader in the industry. Join us in celebrating innovation, collaboration, and the relentless pursuit of scientific advancement. Watch now and see why Cambrex is your trusted partner in pharmaceutical development. |
|
|
|
|
|
|
|
|
|
|
|
|
|
The inability of Novo Nordisk's anti-inflammatory drug to cut cardiovascular events surprised Wall Street on Friday. The company’s stock dropped 9% in early trading, as Elizabeth Cairns reports. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Elizabeth Cairns
|
An anti-inflammatory drug from Novo Nordisk unexpectedly failed in a Phase 3 study that aimed to prove a link between cardiovascular inflammation and heart disease... | |
|
|
|
|
|
|
|
|
by Ayisha Sharma
|
Karyopharm’s stock has plummeted after its second attempt to expand its blood cancer medicine Xpovio into endometrial cancer fell short. Late Thursday, the company reported... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Ratio Therapeutics raises $70M for radiopharma trials: The Boston biotech saidthe Series C funding came from existing investors Duquesne Family Office and Bristol Myers... | |
|
|
|
|
|
|
|
